Investigation announced for Investors in shares of Emisphere Technologies, Inc. (OTC: EMIS) over Takeover
An investigation on behalf of investors of Emisphere Technologies, Inc. (OTC: EMIS) in connection with the proposed takeover.
Investors who purchased shares of Emisphere Technologies, Inc. (OTC: EMIS) and currently hold any of those OTC: EMIS shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain officers and directors of Emisphere Technologies, Inc. breached their fiduciary duties owed to OTC: EMIS investors in connection with the proposed acquisition.
Roseland, NJ based Emisphere Technologies, Inc. operates as a commercial stage pharmaceutical and drug delivery company in the United States. On November 06, 2020, Emisphere Technologies, Inc. announced that it has entered into an agreement with Novo Nordisk A/S (“Novo Nordisk”), whereby Novo Nordisk will acquire Emisphere Technologies, Inc. on a cash-free, debt-free basis, for $1.35 billion in cash. The consideration to be paid per share will depend on the amount of cash and debt at closing, but the Company currently estimates it to be approximately $7.82 per share based on approximately 170.9 million fully diluted shares outstanding.
However, given that MHR Fund Management LLC and the directors of Emisphere (collectively owning a majority of the outstanding Emisphere shares) have already agreed to vote their shares in favor of the transaction, the investigation concerns whether the offer is unfair to OTC: EMIS stockholders. More specifically, the investigation concerns whether the Emisphere Technologies Board of Directors undertook an adequate sales process, adequately shopped the company before entering into the transaction, maximized shareholder value by negotiating the best price, and acted in the shareholders' best interests in connection with the proposed sale.
Those who are current investors in Emisphere Technologies, Inc. (OTC: EMIS) shares have certain options and should contact the Shareholders Foundation.
Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Investors in shares of Emisphere Technologies, Inc. (OTC: EMIS) over Takeover here
News-ID: 2190158 • Views: …
More Releases from Shareholders Foundation
Lawsuit for Investors in Sonder Holdings Inc. (NASDAQ: SOND) filed in effort to …
An investor, who purchased shares of Sonder Holdings Inc. (NASDAQ: SOND), filed a lawsuit over alleged violations of Federal Securities Laws by Sonder Holdings Inc in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Sonder Holdings Inc. (NASDAQ: SOND) have certain options and for certain investors are short and strict deadlines running. Deadline: June 10, 2024. NASDAQ: SOND investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
Lawsuit filed for Investors in Ocugen, Inc. (NASDAQ: OCGN) in effort to recover …
An investor, who purchased shares of Ocugen, Inc. (NASDAQ: OCGN), filed a lawsuit i over alleged violations of Federal Securities Laws by Ocugen, Inc..
Investors who purchased shares of Ocugen, Inc. (NASDAQ: OCGN) have certain options and for certain investors are short and strict deadlines running. Deadline: June 10, 2024. NASDAQ: OCGN investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
Malvern, PA based Ocugen, Inc., a…
Investors who lost money with shares of Evolv Technologies Holdings, Inc. (NASDA …
An investor, who purchased shares of Evolv Technologies Holdings, Inc. (NASDAQ: EVLV), filed a lawsuit in the U.S. District Court for the District of Massachusetts over alleged violations of Federal Securities Laws by Evolv Technologies Holdings, Inc. f/k/a NewHold Investment Corp.
Investors who purchased shares of Evolv Technologies Holdings, Inc. (NASDAQ: EVLV) have certain options and for certain investors are short and strict deadlines running. Deadline: May 24, 2024. NASDAQ: EVLV…
Investigation announced for Investors who purchased shares of Comtech Telecommun …
Comtech Telecommunications Corp is under investigation over potential securities laws violations in connection with certain financial statements.
Investors who purchased shares of Comtech Telecommunications Corp. (NASDAQ: CMTL), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether a series of statements by Comtech Telecommunications Corp. regarding its business, its prospects and its operations were materially false…
More Releases for Emisphere
Insulin Detemir Market to Witness Remarkable Growth by 2027 | Novo Nordisk, MNKD …
Insulin detemir, sold under the brand name Levemir among others, is a long-acting insulin used to treat both sort 1 and type 2 diabetes. It is utilized by infusion under the skin. It is viable for as long as 24 hours. Normal incidental effects incorporate low glucose, hypersensitive responses, torment at the site of infusion, and weight acquire.
Request Sample Copy of Insulin Detemir Market Report: https://www.infinitybusinessinsights.com/request_sample.php?id=598933
Top Key Players Included in…
Oral Biologics Market – Novo Nordisk A/S, Biocon Limited, Oramed Pharmaceutica …
Oral Biologics Market Report 2021 added recently by Coherent Market Insights, evaluates the industry in terms of market size, market share, revenue estimation, and geographical outlook. The study also delivers a precise summary that illustrates the competitive milieu, growth opportunities and application landscape of the Oral Biologics depending on the industry's financial and non-financial impact. The complete range of information related to the Global Oral Biologics Market is obtained through…
Novo Nordisk A/S (NYSE: NVO) Notice: Investigation for Investors in formerly Emi …
An investigation was announced concerning potential securities laws violations in connection with the takeover of Emisphere Technologies, Inc. by Novo Nordisk A/S (NYSE: NVO).
Investors who purchased shares of Emisphere Technologies, Inc. (OTC: EMIS) and currently hold any of those OTC: EMIS shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain officers and…
What's driving the Insulin Detemir Market Growth? Prominent Players: Novo Nordis …
Global "Insulin Detemir Market" 2020 Industry Research Report is an expert and inside and out examination on the flow condition of the Global Insulin Detemir industry. In addition, investigate report sorts the worldwide Insulin Detemir market by top players/brands, area, type and end client. This report likewise examines the different Factors impacting the market development and drivers, further reveals insight into market review, key makers, key received by them, size,…
Anticoagulant Drug Market: Comprehensive study explores Huge Growth in Future| A …
HTF MI recently introduced Global Anticoagulant Drug Market study with in-depth overview, describing about the Product / Industry Scope and elaborates market outlook and status to 2023. The market Study is segmented by key regions which are accelerating the marketization. At present, the market is developing its presence and some of the key players from the complete study are Astrazeneca, Bristol-Myers Squibb CO, Armetheon Inc, Emisphere Technologies, Sun Pharmaceuticals, Abbott…
Non-Insulin Therapies for Diabetes Market 2018 Global Growth Analysis & Forecast …
UpMarketResearch offers a latest published report on “Global Non-Insulin Therapies for Diabetes Market Analysis and Forecast 2018-2023” delivering key insights and providing a competitive advantage to clients through a detailed report. The report contains pages which highly exhibit on current market analysis scenario, upcoming as well as future opportunities, revenue growth, pricing and profitability.
Get Free Exclusive PDF Sample Copy of This Report: https://www.upmarketresearch.com/home/requested_sample/15286
Non-Insulin Therapies for Diabetes Industry research report…